Announcing the start of its ASPIRE (Accessibility Sustainability, Patient-centric, Impact, Responsibility and Equity) program in May 2024, Bristol Myers Squibb is focused on developing strategies to improve access to medicines within global markets.
Bristol Myers Squibb ASPIREs For Access In LMICs
In Vivo spoke with Adam Lenkowsky, executive vice-president, and chief commercialization officer at Bristol Myers Squibb
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
More from Global Vision
• By
The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.
• By
New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.
• By
China's medical equipment industry is growing rapidly, driven by limited domestic presence in high-cost segments and increasing adoption of local products in areas like monitoring equipment, defibrillators, and ventilators. International giants dominate the high-end market, but domestic companies such as Neusoft Medical Systems and Mindray Medical are making significant strides.
• By
Close collaboration between industry, academia and government in employing artificial intelligence could solve the looming threat of antimicrobial resistance, a new report co-authored by Google says.
More from Market Access
• By
Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.
• By
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
• By
Improving reimbursement and integrating digital process across health care should be two priorities for the incoming German coalition, says Martin Walger, chief executive of the IVD industry association, the VDGH, in part two of his interview with In Vivo.